| abstract |
The invention relates to the CGRP antagonists of general formula (I), where R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3</SUP> and R<SUP>4</SUP> are as defined in claim 1, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts thereof and the hydrates of the salts, in particularly the physiologically-acceptable salts with inorganic or organic acids or bases and any compound of general formula (I), in which one or more hydrogen atoms are exchanged for deuterium, medicaments comprising said compounds the use and methods for production thereof. |